GOTTLIEB, A. B.; ARMSTRONG, A. W.; MEROLA, J. F.; NAPOLI, A. .; NOWAK, M.; BANERJEE, S.; LEHMAN, T.; MEASE, P. J. Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s383, 2024. DOI: 10.25251/skin.8.supp.383. Disponível em: https://jofskin.org/index.php/skin/article/view/2678. Acesso em: 22 jul. 2024.